ArticleVirchows Archiv : an international journal of pathology2025
High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumors.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inhibition of the AT-Hook DNA-Binding Domain Attenuates HMGA2-Mediated Epithelial Mesenchyme Transition in Esophageal Cancer Cells.International journal of molecular sciences · 2026Article
- Single-cell RNA sequencing reveals HMGA2 involvement in neoplastic aggressiveness and endothelial cell senescence in chondrosarcoma.Cell biology and toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High mobility group protein 2 (HMGA2) is an essential component of the enhanceosome that regulates gene transcription during organ development, and its re-expression in adult tissues is often linked to tumor formation and progression. To investigate HMGA2's role in cancer, a tissue microarray of 18,582 samples from 154 tumor types and 608 samples from 76 normal tissues was analyzed. HMGA2 expression was generally higher in cancer than in normal tissues. Of the 15,915 tumor samples, 37.5% showed HMGA2 positivity: 12% weak, 11.5% moderate, and 13.9% strong. HMGA2 was detected in at least one case in 118 of 144 tumor categories, with strong staining in 92 categories. The frequency of HMGA2 positivity was highest in cancers of the ovary and the endometrium (52.6-92.6%), thyroidal neoplasms (53.4-95%), salivary gland neoplasms (66.7-98%), and non-seminomatous testicular germ cell tumors (73.5-93.5%). High-level HMGA2 staining was associated with invasive tumor growth of urinary bladder cancers (p < 0.0001); high-grade, advanced pT, metastasis, and poor overall survival (p < 0.0001 each) in clear cell renal cell carcinoma (RCC); nodal metastasis in papillary RCC (p = 0.0099); as well as nodal metastasis in papillary thyroid cancer (p = 0.0063). Low HMGA2 expression was linked to microsatellite instability in colorectal cancer (p = 0.0002) and HPV infection in squamous cell carcinomas (p < 0.0001). It is concluded that HMGA2 is highly expressed in a very broad range of tumor entities. These findings emphasize a potential role of HMGA2 as a drug target and suggest utility for HMGA2 IHC for the distinction of neoplastic from non-neoplastic tissues in several organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.